◀ Back to CDKN1A
CDKN1A — SMAD6
Text-mined interactions from Literome
Pardali et al., J Biol Chem 2000
:
Role of
Smad proteins and transcription factor Sp1 in
p21 ( Waf1/Cip1 ) regulation by transforming growth factor-beta
Medrano et al., Oncogene 2003
(Melanoma...) :
SKI also facilitates cell-cycle progression by targeting the RB pathway by at least two ways : it directly associates with RB and represses its activity when expressed at high levels, and indirectly, it represses
Smad mediated induction of
p21 ( Waf-1 ) This results in increased CDK2 activity, RB phosphorylation, and inactivation
Pardali et al., J Cell Physiol 2005
:
Based on the previously known ability of c-Myc to block p21 expression and epithelial growth arrest in response to TGF-beta1, we demonstrate that ectopic c-Myc expression can abrogate
Smad mediated
p21 induction by all TGF-beta and BMP receptors
Kim et al., Arch Pharm Res 2007
:
Although it has been demonstrated that
p21WAF1/Cip1 could be induced by transforming growth factor-beta1 ( TGF-beta1 ) in a
Smad dependent manner, the cross-talk of Smad signaling pathway with other signaling pathways still remains poorly understood
Lo et al., Molecular cancer 2010
:
In response to TGFbeta stimulation, LMP1 does not abolish
SMAD phosphorylation but
inhibits p21 protein expression
Yilmaz et al., EMBO J 2011
(Melanoma, Experimental) :
Dlx2 counteracts TGFß induced cell-cycle arrest and apoptosis in mammary epithelial cells by at least two molecular mechanisms : Dlx2 acts as a direct transcriptional repressor of TGFß receptor II ( TGFßRII ) gene expression and reduces canonical,
Smad dependent TGFß signalling and expression of the cell-cycle inhibitor
p21 ( CIP1 ) and increases expression of the mitogenic transcription factor c-Myc